Syneos Health Inc stock (US87162W1009): trading update as valuation focus returns after take-private

Syneos Health Inc, the former Nasdaq-listed clinical research and commercial services group, continues to draw interest from investors in unlisted and over-the-counter trading after a 2023 take-private buyout, with recent pricing implying a cautious view on its healthcare outsourcing valuation.

Syneos Health Inc, once listed on Nasdaq under the ticker SYNH in the United States, has remained on investor watchlists even after its 2023 take-private transaction by a private equity consortium led by Elliott Investment Management, Patient Square Capital and Veritas Capital, with recent over-the-counter indications suggesting a subdued valuation compared with listed peers, according to Reuters as of 05/10/2024.

The company, headquartered in Morrisville, North Carolina, was removed from the Nasdaq exchange when the all-cash acquisition closed in 2023, but pricing indications in private markets and secondary venues still reflect sentiment on the U.S. healthcare outsourcing sector and on contract research and commercial services specifically, according to Reuters as of 05/10/2024.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Syneos Health Inc
• Sector/industry: Contract research and commercial services for the biopharmaceutical industry
• Headquarters/country: Morrisville, United States
• Core markets: Biopharmaceutical customers in North America, Europe and other international regions
• Key revenue drivers: Clinical development services and commercialization solutions for new therapies
• Home exchange/listing venue: Formerly Nasdaq (SYNH), now privately held following a 2023 buyout
• Trading currency: USD

Syneos Health Inc: core business model

Syneos Health Inc operates as a global partner for biopharmaceutical companies, combining contract clinical trial execution with outsourced commercialization services that generate revenue from long-term service contracts and project-based engagements.

Recent corporate actions

According to a Reuters report dated 05/10/2024, the private equity buyers of Syneos Health closed their all-cash acquisition in 2023 at USD 43.00 per share, valuing the former Nasdaq-listed group at about USD 7.1 billion including debt and ending its tenure as a U.S. public company.

The transaction followed a strategic review announced in 2022 and took the company off major equity indices such as the S&P MidCap 400, shifting investor access from public-market trading to private equity, secondary stakes and debt instruments linked to the business, according to Reuters as of 05/10/2024.

Valuation metrics and multiples for Syneos Health Inc

Because Syneos Health is now privately owned, current detailed valuation multiples such as forward price/earnings or enterprise value/EBITDA are not disclosed in the way they were when the stock traded on Nasdaq, but the USD 43.00 per share cash consideration agreed in 2023 represented a premium to the company’s undisturbed trading price before the deal talks were announced, based on transaction data reported by Reuters on 05/10/2024.

For investors following the broader U.S. contract research and commercialization sector, valuation benchmarks are now more often drawn from publicly listed peers such as IQVIA and ICON, which continue to publish trading multiples and earnings metrics that can be used as reference points to gauge how a business like Syneos Health might be valued if it were still listed, according to sector comparisons from Reuters as of 05/10/2024.

Conclusion

The key reference point for Syneos Health Inc remains the 2023 take-private price of USD 43.00 per share, which crystallized a public-market valuation and moved the group fully into private ownership. With no ongoing Nasdaq listing, investors now tend to look at publicly traded contract research peers for daily valuation markers, while monitoring Syneos Health’s strategic and financial progress via private equity disclosures and sector news flow, according to Reuters as of 05/10/2024.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.